H.C. Wainwright analyst Robert Burns raised the firm’s price target on Exelixis (EXEL) to $49 from $46 and keeps a Buy rating on the shares following the Q3 report. The firm sees the key value driver for the shares as sentiment on the commercial future for zanzalintinib across various tumor types.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target raised to $51 from $44 at TD Cowen
- Exelixis price target raised to $43 from $41 at Stifel
- Exelixis price target raised to $41 from $40 at Barclays
- Exelixis’s Strong Financial Performance and Growth Prospects Earns Buy Rating from Yaron Werber
- Exelixis Reports Strong Q3 2025 Financial Results